Restenosis after coronary angioplasty: An overview

Journal of the American College of Cardiology

Volumn 17, Issue 6 SUPPL. 2, 1991, Pages 2-13

  Califf, Robert M ^a   Fortin, Donald F ^a   Frid, David J ^a   Harlan III, William R ^a   Ohman, E Magnus ^a   Bengtson, James R ^a   Nelson, Charlotte L ^a   Tcheng, James E ^a   Mark, Daniel B ^a   Stack, Richard S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; FISH OIL; MEVINOLIN; PROSTACYCLIN; VASODILATOR AGENT;

ATHEROSCLEROSIS; CONFERENCE PAPER; CORONARY ARTERY DILATATION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE;

ANGIOPLASTY, LASER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMAL; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DISEASE MODELS, ANIMAL; FOLLOW-UP STUDIES; HUMAN; RECURRENCE; STENTS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025890989     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(91)90933-Z     Document Type: Article

References (79)

1. Plaque fissuring: the cause of acute myocardial infarction sudden ischemic death, and crescendo angina
2. The development and use of animal models in atherosclerotic research
3. Animal models and the study of atherosclerosis
4. The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi
5. Acute effects of transluminal angioplasty in three experimental models of atherosclerosis
6. Atherosclerotic Yucatan microswine: an animal model with high-grade, fibroosific, nonfatty lesions suitable for testing catheter-based interventions
7. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon
8. Estimation of the effects of angioplasty on coronary stenosis using quantitative video angiography
9. Does an optimal luminal result after PTCA reduce restenosis?
10. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty
11. Densitometrically observed differences in elastic recoil of the angioplasty (abstr)
12. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients
13. Comparison of automated quantitative coronary angiography with caliper measurements of percent diameter stenosis
14. Assessment of short-, medium-, and long-term variations in arterial dimensions from computerassisted quantitation of coronary cineangiograms
15. Change in diameter of coronary artery segments adjacent to stenosis after percutaneous transluminal coronary angioplasty: failure of percent diameter stenosis measurement to reflect morphologic changes induced by balloon inflation
16. Is routine automated quantitative analysis of coronary arteriography feasible? Evaluation of operator-dependent variables inherent to the technique (abstr)
17. Overview of diagnostic test assessment
18. Exercise electrocardiographic and functional responses after percutaneous transluminal coronary angioplasty
19. Detection of restenosis after elective percutaneous transluminal coronary angioplasty using the exercise treadmill test
20. Exercise treadmill testing is a poor predictor of anatomic restenosis after angioplasty for acute myocardial infarction
21. Very early prediction of restenosis after successful coronary angioplasty: anatomic and functional assessment
22. Usefulness of early radionuclide angiography for identifying low-risk patients for late restenosis after percutaneous transluminal coronary angioplasty
23. Early detection of restenosis after successful percutaneous transluminal coronary angioplasty by exercise-redistribution thallium scintigraphy
24. Exercise electrocardiography and myocardial scintigraphy in the serial evaluation of the results of percutaneous transluminal coronary angioplasty
25. The value of exercise tests in the follow-up of patients who underwent transluminal coronary angioplasty
26. Predictive value of early maximal exercise test and thallium scintigraphy after successful percutaneous transluminal coronary angioplasty
27. Exercise radionuclide ventriculography in evaluating successful transluminal coronary angioplasty
28. Restenosis after transluminal coronary angioplasty detected with exercise-gated radionuclide ventriculography
29. Predicting late restenosis after coronary angioplasty by very early (12 to 24 h) thallium-201 scintigraphy: implications with regard to mechanisms of late coronary restenosis
30. Clinical significance of perfusion defects by thallium-201 single photon emission tomography following oral dipyridamole early after coronary angioplasty
31. Can dipyridamole thallium imaging predict restenosis after coronary angioplasty?
32. Exercise echocardiography is a valuable adjunct to treadmill testing for detection of restenosis after coronary angioplasty (abstr)
33. Exercise echocardiography correctly predicts restenosis in patients undergoing emergent PTCA for non-Q wave myocardial infarction (abstr)
34. Usefulness of high-dose dipyridamole echocardiography test in coronary angioplasty
35. Long-term outcome of patients with asymptomatic restenosis after percutaneous coronary angioplasty
36. Restenosis: the clinical issues
37. Restenosis after PTCA is increased in diabetic patients (abstr)
38. Risk factors for recurrent stenosis following successful coronary angioplasty
39. Identifying patients at high risk for restenosis after percutaneous transluminal coronary angioplasty for unstable angina pectoris
40. Restenosis after transluminal coronary angioplasty: a risk factor analysis
41. Increased frequency of restenosis in patients continuing to smoke cigarettes after percutaneous transluminal coronary angioplasty
42. Lipoproteins predict restenosis after PTCA (abstr)
43. Does serum LP(a) predict restenosis after PTCA? (abstr)
44. Serum lipoprotein levels fail to predict postangioplasty recurrent coronary artery stenosis
45. Association of a significant increase of plasminogen activator inhibitor-1 with the development of coronary restenosis in patients after PTCA (abstr)
46. Impaired fibrinolytic capacity and tissue plasminogen activator release in patients with restenosis after percutaneous transluminal coronary angioplasty (PTCA)
47. Neutrophil activation after PTCA in humans (abstr)
48. Evidence for neutrophil and complement activation early after PTCA (abstr)
49. Short-and long-term outcome of percutaneous transluminal coronary angioplasty in chronic dialysis patients
50. A practical porcine model of human coronary artery restenosis post PTCA (abstr)
51. Prolonged autoperfusion angioplasty: immediate clinical outcome and angiographic follow-up
52. Restenosis following directional coronary atherectomy of native coronary arteries (abstr)
53. Multicenter registry of coronary atherectomy using the transluminal extraction-endarterectomy catheter (abstr)
54. Restenosis rate after coronary stem implantation: angiographic assessment of the initial series (abstr)
55. Intracoronary stenting to prevent Schatz stent suggest benefit in selected high risk patients (abstr)
56. Percutaneous excimer laser coronary and angioplasty results of the first 110 procedures (abstr)
57. A multi-center trial of laser balloon angioplasty for abrupt closure following PTCA (abstr)
58. Coumadin and aspirin in prevention of recurrence after translumtnal coronary angioplasty: a randomized study
59. Neither ticlopidine nor aspirin-dipyridamole prevents restenosis post PTCA: results from a randomized placebo-controlled multicenter trial (abstr)
60. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty
61. Aspirin versus placebo after coronary angioplasty for prevention of restenosis (abstr)
62. A randomized trial of aspirin in PTCA: effect of high vs low dose aspirin on major complications and restenosis (abstr)
63. Effect of high dose and low dose aspirin on restenosis after primary successful angioplasty (abstr)
64. High vs low dosage of acetylic salicylic acid for prevention of restenosis after successful PTCA preliminary results of a randomized trial (abstr)
65. Restenosis after angioplasty overview of clinical trials using aspirin and omega-3 fatty acids (abstr)
66. Coronary angioplasty: antiplatelet therapy reduces acute reduces acute complications but not resteosis (abstr)
67. Combined use of aspirin, ticlopidine and nicorandil prevented restenosis after coronary angioplasty (abstr)
68. Effect of transluminal coronary angioplasty
69. Prostaglandin E1 infusion after angioplasty in humans inhibits abrupt occlusion and early restenosis
70. Effect of 18-to plicated coronary angioplasty
71. Failure of diltiazem lo prevent restenosis after percutaneous transluminal coronary angioplasty
72. Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty
73. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids
74. Determinants of restenosis and lack of effect of dietary supplementation with eicosapentaenoic acid on the incidence of coronary artery restenosis after angioplasty
75. Usefulness of fish oil supplements in preventing clinical evidence of restenosis after percutaneous transluminal coronary angioplasty
76. Randomized trial offish oil for prevention of restenosis after coronary angioplasty
77. Can oral fish oil supplement minimize restenosis after percutaneous percataneous transluminal coronary angioplasty? (abstr)
78. Prevention of restenosis by lovastatin (abstr)
79. Lipid lowering for the prevention of recurrent stenosis following coronary angioplasty (abstr)